Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New Eye-Tracking app could spot brain changes early

NCT ID NCT05212727

Knowledge-focused Sponsor: Innodem Neurosciences Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aimed to create a non-invasive eye-tracking software to detect cognitive changes in people with neurological disorders. Researchers tested 300 adults with simple cognitive tasks while tracking their eye movements. The data was used to train machine learning algorithms to identify signs of conditions like multiple sclerosis or dementia. The study was terminated early, so results are limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

300 people

The number who actually took part.

Started

Apr 2022

Finished

May 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Data will be obtained from 300 healthy adult individuals across the age spectrum. We will stop recruiting participants of a certain age once one of the following age groups has reached 100 participants: 18-40 40-60 60 and over

Ages

18 years and older

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged 18 years old and above * A score of ≥ 26 on the Montreal Cognitive Assessment (MoCA) * Able to provide informed consent * Visual acuity of 20/100 in at least one eye (corrective glasses, contact lenses, surgery etc are permitted). Exclusion Criteria: * Evidence or medical history of psychiatric issues, which are known to also affect movements and oculomotor control. * Evidence or history of significant neurological disorder (e.g. MS, PD, ALS, Dementia) * Use of prescription drugs known to influence ocular motor visual function, such as benzodiazepines, antipsychotics, and anticonvulsants. * Diagnosed with an active substance use disorder. * History of stroke. * Recent traumatic brain injury (within the last 6 months).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Neurological disorders are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

nervous system disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Neurological disorders

Contacts and locations

Locations

  • Innodem Neurosciences

    Montreal, Quebec, H2T 2A4, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.